Frank Nazzario, RPh, joined Larimar Therapeutics in April 2024 as Vice President of Commercial and brings nearly 30 years’ experience in biologics and rare disease launch leadership. Most recently, Mr. Nazzario was with BioCryst Pharmaceuticals where he served as Senior Vice President of Sales and prior to that, Vice President of Marketing. His additional experience includes commercial leadership roles at Spark Therapeutics, where he led the marketing team responsible for the launch and commercialization of Luxturna®, the first FDA-approved gene therapy for an inherited retinal disorder, and ViroPharma, Inc., where as Director of Marketing, Americas, he led the launch of Cinryze®, the first approved biologic for Hereditary Angioedema.
Frank obtained his pharmacy degree from the Philadelphia College of Pharmacy & Science and earned his MBA from St. Joseph’s University in Philadelphia.